CanSinoBIO's inhaled COVID-19 vaccine Convidecia Air approved in China

6 September 2022
china_regulator_cnmpa_big

CanSino Biologics (SSE: 688185, HK: 06185) has announced that the National Medical Products Administration of China (NMPA) has granted the company emergency use authorization for its recombinant COVID-19 vaccine (Adenovirus Type 5 Vector) for Inhalation, trade name Convidecia Air, to be used as a booster dose.

As a result, China became the first country to approve a needle-free, inhaled version of a COVID-19 vaccine.

CanSino Biologics’ stock price surged by over 14% in both the Chinese mainland and Hong Kong markets on Monday, closing up 9.8% at 141.50 renminbi.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology